Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating if, for patients with clinically node-positive breast cancer undergoing upfront surgery, treatment with tailored axillary surgery TAS combined with axillary radiotherapy ART is better than axillary lymph node dissection ALND in improving arm-related quality of life QoL and reducing lymphedema two years after treatment. ALND is currently the standard treatment but is associated with major side effects. TAS targets positive lymph nodes more selectively than ALND, potentially causing less harm when combined with ART. The study compares two treatment approaches one group undergoes ALND, the standard surgery removing all lymphatic tissue in the axilla, alongside breast irradiation excluding the axilla the other group receives TAS, which includes sentinel lymph node biopsy and targeted removal of suspicious nodes, combined with breast and axillary radiotherapy ART. All patients receive adjuvant breast irradiation following breast-conserving surgery, with or without axillary radiotherapy depending on their group. The trial follows participants from surgery through post-treatment monitoring. Participants will be assessed from baseline through two years after randomization to monitor changes in arm-related QoL and the occurrence of lymphedema. Researchers will collect quality of life questionnaires and clinical evaluations to measure these outcomes. The study includes randomization into treatment groups and involves regular follow-up to assess long-term effects on arm function and side effects. The overall goal is to determine if TAS plus ART offers improved quality of life compared to ALND.
Actively Recruiting
Researchers are investigating whether adding a new medicine called tirzepatide, a glucose-dependent insulinotropic polypeptide GIPglucagon-like peptide-1 receptor agonist GLP-1RA, to usual insulin therapy can improve blood sugar control in adults with type 1 diabetes T1D. The study is designed as a prospective, randomized clinical trial to evaluate this combinations effect on glucose management, aiming to provide new options beyond standard insulin treatment. About 30% of adults with T1D currently meet recommended blood sugar targets, highlighting the need for improved therapies. The study will enroll adults aged 18 to 65 years with T1D diagnosed for at least 12 months who are already using automated insulin delivery AID systems. Participants will be randomly assigned to either continue their standard care or to add once-weekly injections of tirzepatide, starting at a low dose of 2.5 mg and increasing to 5 mg weekly for 12 weeks. The trial includes a 4-week dose titration phase followed by 12 weeks of treatment, comparing glucose control outcomes between groups. Participants will wear a continuous glucose monitor CGM and share their glucose and insulin data throughout the 16-week study. Researchers will assess time spent within target glucose ranges, changes in blood sugar levels, insulin doses, and body weight. Safety and adherence will be monitored during the trial. The study aims to gather important data on whether tirzepatide can help improve glucose control and quality of life for adults living with T1D.